POLATUZUMAB VEDOTIN

BRAND NAME: POLIVY

DRUG CLASS: Cytotoxic cancer therapy, monoclonal antibody (humanised) and antimitotic agent

AVAILABILITY: Vial contains 30 mg or 140 mg of polatuzumab vedotin.[1]
Also contains succinic acid, sodium hydroxide, sucrose and polysorbate-20.[1]

WARNING: Cytotoxic.[1] Strict handling precautions are required. Check your local guidelines for handling of cytotoxic medicines and related waste.

pH: 5.3 when reconstituted[2]

PREPARATION: **In a cytotoxic drug safety cabinet**:
Reconstitute the 30 mg with 1.8 mL or the 140 mg vial with 7.2 mL of water for injections, directed down the wall of the vial. Swirl gently until dissolved. **Do not shake**. The concentration is 20 mg/mL.
The solution is clear to slightly opalescent and colourless to light brown.[1]
Dilute the dose in a minimum of 50 mL of a compatible fluid. The final concentration should be 0.72–2.7 mg/mL. Mix by gently inverting the bag. **Do not shake**.[1]
Excessive agitation of the solution can cause aggregation. If the solution must be transported, see the product information for further instructions and stability information.[1]

STABILITY: Vial: store at 2 to 8 °C. Do not freeze. Protect from light.[1]
When prepared by pharmacy under aseptic conditions:
Reconstituted solution: stable for 20 hours below 25 °C and 72 hours at 2 to 8 °C.[1]
Infusion solution[1]:

Fluid used	Below 25 °C	At 2 to 8 °C
Glucose 5%	8 hours	72 hours
Sodium chloride 0.45%	4 hours	36 hours
Sodium chloride 0.9%	4 hours	72 hours

ADMINISTRATION
IM injection: Not recommended
SUBCUT injection: Not recommended
IV injection: Not recommended[1]
IV infusion: Infuse the first dose over 90 minutes. If well-tolerated subsequent infusions can be given over 30 minutes.[1] Use a low protein-binding 0.2 or 0.22 micrometre filter.[1]

COMPATIBILITY: Sodium chloride 0.9%[1], sodium chloride 0.45%[1], glucose 5%[1]

INCOMPATIBILITY: No information

SPECIAL NOTES: Premedication with an antihistamine and paracetamol is recommended.[1]
Monitor for infusion reactions during the infusion and for 90 minutes after the first infusion, and 30 minutes after subsequent infusions.[1]
Dizziness after the infusion is very common.[1]
Minimal emetogenic risk.[3] Check your local guidelines for premedication requirements

REFERENCES
1. Product information. Available from www.tga.gov.au. Accessed 22/05/2025.
2. Medical information. pH following Polivy (polatuzumab) reconstitution. Sydney: Roche Products; 26/03/2020.
3. Clinical resource. Prevention of anti-cancer therapy induced nausea and vomiting [v5 May 2021]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 08/04/2023.